Join MitoAction and Dr. Madhu Davies from Reneo Pharmaceuticals for our February Monthly Mito Expert Series titled “Patients as Partners in Drug Development.”
Dr. Madhu Davies, MB, ChB, MRCG,P FFPM, MBA, is the medical director at Reneo Pharmaceuticals. Previously, Madhu has served many roles at companies developing medicines to patients with rare . For more than 25 years, she has provided leadership and advisory services working in clinical development, safety, regulatory programs, gaining broad experience of drug development including biologics, small molecules and vaccines. Madhu has held significant pharmaceutical roles as medical director and CMO, in addition to medical affairs.
Madhu trained in medicine in the United Kingdom and maintains an active academic interest as Visiting Professor at Cardiff University; she is Director of the Postgraduate Course in Pharmaceutical Medicine and has also edited or contributed to several textbooks and journals.
Dr. Michio Hirano, Chief of the Neuromuscular Division at Columbia University Medical Center, and Kris Engelstad MS CGC, a board-certified genetic counselor and program...
When a genetic variant is shared by only a handful of individuals worldwide, what does it mean for diagnosis, treatment, and research? In this...
Cheryl M. Clow RN discusses Getting Through the Day with Mito: Treatments, Supplements, and Humor. Topics of discussion include: Patient care considerations and making...